Trials / Unknown
UnknownNCT04971369
Safety Study of 89Zr-NY001 PET Imaging in Patients
Safety Study of 89Zr-NY001 PET Imaging in Patients With Fibronectin ED-B Positive Solid Tumors
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Wuxi No. 4 People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled NY001 (89Zr-NY001) PET imaging in patients with fibronectin ED-B domain positive solid tumors.
Detailed description
After being fully informed about the study and potential risks, all patients giving written informed consent will be evaluated to determine eligibility for study entry. Patients will receive an injection of 89Zr-NY001 and will undergo PET/CT scanning to determine uptake of 89Zr-NY001 in tumor lesions and the whole body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 89Zr-NY001 | 89Zr-NY001 injection followed by 89Zr-NY001 PET scan |
Timeline
- Start date
- 2021-08-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2021-07-21
- Last updated
- 2021-07-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04971369. Inclusion in this directory is not an endorsement.